Modality
Degrader
MOA
CD3xCD20
Target
MDM2
Pathway
Innate Imm
Breast Ca
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
Apr 2018
→ Jul 2031
Phase 2Current
NCT06571206
1,177 pts·Breast Ca
2024-01→2031-07·Completed
NCT06702176
2,577 pts·Breast Ca
2018-04→2028-08·Terminated
3,754 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-08-122.4y awayPh3 Readout· Breast Ca
2031-07-145.3y awayPh3 Readout· Breast Ca
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Termina…
P2/3
Complet…
Catalysts
Ph3 Readout
2028-08-12 · 2.4y away
Breast Ca
Ph3 Readout
2031-07-14 · 5.3y away
Breast Ca
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06571206 | Phase 2/3 | Breast Ca | Completed | 1177 | PANSS |
| NCT06702176 | Phase 2/3 | Breast Ca | Terminated | 2577 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 |